The study comparing the incidence of cardiovascular events between high-dose ARB [angiotensin II receptor antagonists] monotherapy and combination therapy with ARB and calcium channel blocker in Japanese elderly hypertensive patients at high cardiovascular risk.

Trial Profile

The study comparing the incidence of cardiovascular events between high-dose ARB [angiotensin II receptor antagonists] monotherapy and combination therapy with ARB and calcium channel blocker in Japanese elderly hypertensive patients at high cardiovascular risk.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2015

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Amlodipine; Azelnidipine; Calcium channel antagonists
  • Indications Cardiovascular disorders; Hypertension
  • Focus Therapeutic Use
  • Acronyms OSCAR
  • Most Recent Events

    • 05 Apr 2011 Results presented as a late-breaking abstract at the 60th Annual Scientific Session of the American College of Cardiology.
    • 04 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jul 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top